Screener
Chemours CC Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $1.59B-1.5% | $1.38B+1.0% | $1.33B-2.2% | $1.5B-0.9% | $1.62B+3.9% | ||
| $1.31B-2.4% | $1.17B+3.3% | $1.17B+7.3% | $1.26B+3.3% | $1.34B+7.3% | ||
| $286M+2.9% | $212M-10.2% | $155M-41.5% | $233M-18.5% | $278M-9.7% | ||
| 18%+0.8pp | 15.4%-1.9pp | 11.7%-7.8pp | 15.6%-3.4pp | 17.2%-2.6pp | ||
| $27M-3.6% | $26M-3.7% | $27M+3.8% | $26M-10.3% | $28M+7.7% | ||
| $469M+10.6% | $147M+19.5% | $130M-23.5% | $122M-10.9% | $424M+175% | ||
| $499M+6.2% | $186M+1.6% | $161M-21.1% | $152M-43.1% | $470M+157% | ||
| $68M+1.5% | $69M+4.5% | $68M+1.5% | $68M0.0% | $67M+1.5% | ||
| $273M+13,550% | $22M+340% | $3M— | $16M+167% | $2M+300% | ||
| -$1M+99.6% | -$22M— | -$67M-6,800% | $38M+219% | -$248M-459% | ||
| $273M+108% | $7M+40.0% | —— | -$8M— | $131M+1,356% | ||
| -$274M+27.9% | -$29M-480% | -$47M-327% | $46M+244% | -$380M-733% | ||
| -17.2%+6.3pp | -2.1%-1.7pp | -3.5%-2.7pp | 3.1%+5.2pp | -23.5%-27.4pp | ||
| -$1.81+28.5% | -$0.19-533% | -$0.31-287% | $0.31+241% | -$2.53-749% | ||
| $147M+263% | $126M-18.2% | $82M-42.3% | $186M+70.6% | -$90M-143% | ||
| 9.2%+14.8pp | 9.1%-2.1pp | 6.2%-4.3pp | 12.4%+5.2pp | -5.6%-19.0pp | ||
| $67M+137% | $47M-28.8% | $1M-98.5% | $106M+194% | -$181M-234% |
FAQ
- What is Chemours's revenue?
- Chemours (CC) generated $5.8B in revenue over the trailing twelve months, down 0.9% year over year.
- Is Chemours profitable?
- Chemours is not currently profitable: it reported a net loss of $304.0M over the trailing twelve months, a -5.2% net margin.
- What is Chemours's earnings per share?
- Chemours's diluted EPS over the trailing twelve months is $-2.00.
- Where does Chemours's income statement data come from?
- Every line is extracted from Chemours's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
